Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis

Abstract

In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0‐6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).

Metadata

Item Type:	Article
Authors/Creators:	Cortes, J Twelves, C
Copyright, Publisher and Additional Information:	© 2019 The Authors. The Breast Journal published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords:	advanced breast cancer; efficacy analysis; eribulin; overall survival; safety
Dates:	Accepted: 18 October 2019 Published (online): 29 November 2019 Published: 22 July 2020
Institution:	The University of Leeds
Depositing User:	Symplectic Publications
Date Deposited:	17 Jan 2020 13:33
Last Modified:	25 Jun 2023 22:07
Status:	Published
Publisher:	Wiley
Identification Number:	10.1111/tbj.13686
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:155731

Download

Published Version

Filename: final VoR tbj.13686.pdf

Licence: CC-BY 4.0

CLICK TO DOWNLOAD

CORE (COnnecting REpositories)

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis

Abstract

Metadata

Download

Published Version

Export

Statistics